Evidence map›Paper›PMID 40289289›Full record

ArticleClinical and translational science2025

Low Dose Methotrexate Has Divergent Effects on Cycling and Resting Human Hematopoietic Stem and Progenitor Cells.

Maximilien Lora, H A Ménard, Anastasia Nijnik, David Langlais, Marie Hudson, Inés Colmegna

Abstract read
In one paragraph

Article in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maximilien LoraThe Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Canada.
H A MénardProfessor Emeritus Division of Rheumatology, Department of Medicine, McGill University and RI-MUHC, Montreal, Canada.
Anastasia NijnikDepartment of Physiology; McGill Research Centre on Complex Traits, McGill University, Montreal, Canada.ORCID 0000-0001-6048-4631
David LanglaisResearch Centre on Complex Traits, Dahdaleh Institute of Genomic Medicine, Department of Human Genetics, Department of Microbiology and Immunology, McGill University, Montreal, Canada.ORCID 0000-0003-4429-0110
Marie HudsonDivision of Rheumatology, Department of Medicine, McGill University & Lady Davis Institute, Montreal, Canada.ORCID 0000-0001-6718-2468
Inés ColmegnaThe Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Canada.ORCID 0000-0002-8091-8334

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Low dose methotrexate (LD-MTX) remains the gold standard in rheumatoid arthritis (RA) therapy. Multiple mechanisms on a variety of immune cells contribute to the anti-inflammatory effects of LD-MTX. Inflammatory signaling is deeply implicated in hematopoiesis by regulating hematopoietic stem and progenitor cell (HSPC) fate decisions; raising the question of whether HSPC are also modulated by LD-MTX. This is the first study to characterize the effects of LD-MTX on HSPC. CD34

Indexed as

Hematopoietic Stem CellsMethotrexateAntigens, CD34Arthritis, RheumatoidCell CycleCell ProliferationCells, CulturedCell SurvivalDose-Response Relationship, DrugHumansReactive Oxygen SpeciesReduced Folate Carrier ProteinAntigens, CD34MethotrexateReactive Oxygen SpeciesReduced Folate Carrier Proteinarthritishematopoietic stem cellsHSPCmethotrexateMTXrheumatoid

Identifiers

PMID40289289
PMCPMC12034572

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.